Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (261-270 of 430) with videos related to

Pageof 43
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2010
Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agentsBrian C Geyer, Latha Kannan, Pierre-Emmanuel Garnaud, et al.
The Lancet. Oncology|August 21, 2012
Treatment of breast cancer during pregnancy: an observational studySibylle Loibl, Sileny N Han, Gunter von Minckwitz, et al.
Pharmacogenomics|August 12, 2011
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patientsRon H N van Schaik, Marleen Kok, Fred C G J Sweep, et al.
The Lancet. Oncology|June 29, 2026
Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry studyAnnefleur J W Mauritz, Linda de Munck, Janine M Simons, et al.
Eclinicalmedicine|March 30, 2023
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialVivianne C G Tjan-Heijnen, Senna W M Lammers, Sandra M E Geurts, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Cancer Research|March 8, 2012
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumorsSven Rottenberg, Marieke A Vollebergh, Bas de Hoon, et al.
The Lancet. Oncology|November 11, 2018
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trialMette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, et al.
JAMA Oncology|May 20, 2021
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 TrialAnna van der Voort, Mette S van Ramshorst, Erik D van Werkhoven, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2023
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancerYuwei Wang, Annegien Broeks, Daniele Giardiello, et al.
Pageof 43

Showing results (261-270 of 430) with videos related to

Sort By:
Pageof 43
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2010
Plant-derived human butyrylcholinesterase, but not an organophosphorous-compound hydrolyzing variant thereof, protects rodents against nerve agentsBrian C Geyer, Latha Kannan, Pierre-Emmanuel Garnaud, et al.
The Lancet. Oncology|August 21, 2012
Treatment of breast cancer during pregnancy: an observational studySibylle Loibl, Sileny N Han, Gunter von Minckwitz, et al.
Pharmacogenomics|August 12, 2011
The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patientsRon H N van Schaik, Marleen Kok, Fred C G J Sweep, et al.
The Lancet. Oncology|June 29, 2026
Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry studyAnnefleur J W Mauritz, Linda de Munck, Janine M Simons, et al.
Eclinicalmedicine|March 30, 2023
Extended adjuvant aromatase inhibition after sequential endocrine therapy in postmenopausal women with breast cancer: follow-up analysis of the randomised phase 3 DATA trialVivianne C G Tjan-Heijnen, Senna W M Lammers, Sandra M E Geurts, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Cancer Research|March 8, 2012
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumorsSven Rottenberg, Marieke A Vollebergh, Bas de Hoon, et al.
The Lancet. Oncology|November 11, 2018
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trialMette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, et al.
JAMA Oncology|May 20, 2021
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 TrialAnna van der Voort, Mette S van Ramshorst, Erik D van Werkhoven, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2023
External validation and clinical utility assessment of PREDICT breast cancer prognostic model in young, systemic treatment-naïve women with node-negative breast cancerYuwei Wang, Annegien Broeks, Daniele Giardiello, et al.
Pageof 43